Articles tagged with: OPD5
Press Releases»

Stockholm, Sweden (Press Release) – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 – a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC).
Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as a myeloablative regimen followed by autologous stem cell transplantation in patients with relapsed refractory multiple myeloma. The specific formulation enables administration of high …